Covered recipient · General Payments record
JOHN P LAMBETH
Allopathic & Osteopathic Physicians Internal Medicine Endocrinology, Diabetes & Metabolism
General Payments · PY2018–2024
$52,466.27
- Reported across 115 records
- CMS publication 2026-01-23
Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.
How these totals are calculated
- The total is the sum of the General Payments records CMS published for the labeled program year(s), exactly as published. Nothing is estimated, weighted, or combined across categories.
- General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
- Featured-page threshold (a presentation gate, not a judgment): records>=3 OR total>=100 (all years).
- Methodology & Data — sourcing, labeling, and limitations.
By nature of payment
PY2024 · sorted by reported total
| Nature of payment | Amount | Records |
|---|---|---|
| Food and Beverage | $225.47 | 19 |
By paying entity
PY2024 · sorted by reported total
| Paying entity | Amount | Records |
|---|---|---|
| Novo Nordisk AS | $183.32 | 17 |
| Insulet Corporation | $24.06 | 1 |
| CeQur Corporation | $18.09 | 1 |
By program year
All program years on this page · sorted by year
Payment records · PY2024 (19)
Sorted by paying entity, then date · as published by CMS
| Paying entity | Amount | Date | Nature of payment | Dispute status | Published | Record ID | Source |
|---|---|---|---|---|---|---|---|
| CeQur Corporation | $18.09 | 06/17/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1126846104 | CMS |
| Insulet Corporation | $24.06 | 11/11/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1116821850 | CMS |
| Novo Nordisk Inc | $10.02 | 01/22/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1097283514 | CMS |
| Novo Nordisk Inc | $16.19 | 01/26/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1097725044 | CMS |
| Novo Nordisk Inc | $4.05 | 02/21/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1097263551 | CMS |
| Novo Nordisk Inc | $14.62 | 03/18/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1096624738 | CMS |
| Novo Nordisk Inc | $19.56 | 04/22/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1096694376 | CMS |
| Novo Nordisk Inc | $8.65 | 05/22/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1096929894 | CMS |
| Novo Nordisk Inc | $3.21 | 05/23/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1096937099 | CMS |
| Novo Nordisk Inc | $18.23 | 06/03/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1097434617 | CMS |
| Novo Nordisk Inc | $4.33 | 06/12/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1097321585 | CMS |
| Novo Nordisk Inc | $17.45 | 08/06/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1096590681 | CMS |
| Novo Nordisk Inc | $4.83 | 08/06/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1096697298 | CMS |
| Novo Nordisk Inc | $0.64 | 08/06/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1097307379 | CMS |
| Novo Nordisk Inc | $14.96 | 08/14/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1096608804 | CMS |
| Novo Nordisk Inc | $23.22 | 09/17/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1096785446 | CMS |
| Novo Nordisk Inc | $8.33 | 11/26/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1097636127 | CMS |
| Novo Nordisk Inc | $8.08 | 12/02/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1096571930 | CMS |
| Novo Nordisk Inc | $6.95 | 12/09/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1096597116 | CMS |
Source & provenance
- Dataset
- CMS Open Payments — General Payments
- Publisher of source data
- Centers for Medicare & Medicaid Services
- CMS publication date
- 2026-01-23
- Program years on this page
- 2018, 2019, 2020, 2023, 2024
- Generated from
- OP_DTL_GNRL_PGYR2024_P01232026_01102026.csv
One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.
Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.